Genovate Biotechnology Co Ltd (4130) — Cash Flow-to-Debt Ratio
Genovate Biotechnology Co Ltd (4130) has a Cash Flow-to-Debt Ratio of 0.13x as of December 2025, meaning its operating cash flow of NT$16.93 Million could theoretically repay 0% of its total liabilities (NT$126.05 Million) in one year. See Genovate Biotechnology Co Ltd (4130) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Genovate Biotechnology Co Ltd Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Genovate Biotechnology Co Ltd across 11 annual periods. Also explore 4130 net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Genovate Biotechnology Co Ltd (2015–2025)
Year-by-year debt coverage analysis for Genovate Biotechnology Co Ltd. For market capitalisation and broader financial context, see 4130 market cap overview.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.35x | NT$43.79 Million | NT$126.05 Million | ▼ -11.1% |
| 2024 | 0.39x | NT$55.11 Million | NT$141.08 Million | ▼ -39.3% |
| 2023 | 0.64x | NT$84.78 Million | NT$131.69 Million | ▲ +6449.1% |
| 2022 | 0.01x | NT$1.51 Million | NT$153.60 Million | ▲ +107.8% |
| 2021 | -0.13x | NT$-17.26 Million | NT$136.65 Million | ▼ -121.0% |
| 2020 | 0.60x | NT$87.08 Million | NT$144.87 Million | ▲ +122.8% |
| 2019 | 0.27x | NT$44.43 Million | NT$164.68 Million | ▼ -26.1% |
| 2018 | 0.36x | NT$62.88 Million | NT$172.32 Million | ▲ +415.8% |
| 2017 | 0.07x | NT$31.27 Million | NT$442.06 Million | ▼ -60.2% |
| 2016 | 0.18x | NT$70.58 Million | NT$397.04 Million | ▲ +114.7% |
| 2015 | 0.08x | NT$32.53 Million | NT$392.95 Million | — |